Zhuang XD, et al. - Researchers explored the comparative cardiovascular (CV) safety of novel anti-diabetic agents in this network meta-analysis utilizing studies (randomized controlled trials) comparing anti-diabetic drugs with other comparators in adults with type 2 diabetes. Also, they performed a post hoc correlation analysis of severe hypoglycemia and primary outcome as per ranking order. Findings demonstrated favorable CV safety profile of novel anti-diabetic agents, although small but robust differences were reported between individual agents. A concomitant increase in the risk of severe hypoglycemia was held partly responsible for the observed increase in CV risk, for which sulfonylureas performed the worst.